|
Volumn 40, Issue 9, 2012, Pages 2737-2738
|
Antifungal therapy in the critically ill: In medio stat virtus: Is a preemptive approach correct?
a a a a |
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTIFUNGAL AGENT;
ANTIFUNGAL THERAPY;
ANTIMICROBIAL THERAPY;
BLOODSTREAM INFECTION;
CANDIDEMIA;
CANDIDIASIS;
COMORBIDITY;
CRITICALLY ILL PATIENT;
DISEASE SEVERITY;
ENTEROCOCCUS;
FUNGAL COLONIZATION;
HUMAN;
IMMUNOCOMPROMISED PATIENT;
INTENSIVE CARE UNIT;
LETTER;
MORTALITY;
PRIORITY JOURNAL;
RISK FACTOR;
STAPHYLOCOCCUS AUREUS;
ANTIFUNGAL AGENTS;
FEMALE;
HUMANS;
MALE;
|
EID: 84865515239
PISSN: 00903493
EISSN: 15300293
Source Type: Journal
DOI: 10.1097/CCM.0b013e318258ebb2 Document Type: Letter |
Times cited : (2)
|
References (8)
|